Category Archive: News

  1. Biogelx Announces New Chairman

    Leave a Comment
    International 3D hydrogel and bioink manufacturer, Biogelx, has announced the appointment of a new Chairman.

    The company’s Board of Directors have unanimously elected John Waddell to succeed retiring Chairman, Douglas Hutchison who has stepped down from the role after supporting Biogelx since they were established in 2013.

    It’s been an honour to work with the Biogelx team over the past six years and see the company evolve and grow.  3D Cell Culture and 3D Bioprinting are exciting technology areas and John is the ideal person to guide Biogelx through their next phase of development” stated Douglas. “

    Biogelx has been developing their synthetic peptide hydrogels since 2013 and is preparing to launch it’s a new range of commercial BiogelxTM-Inks, suitable for a range of bioprinting applications.

    John was a solicitor and has extensive experience of driving value and leading early stage high growth companies to successful exit.  In his early career John worked for Christian Salvesen where he led more than sixty global M&A transactions, more recently he was CEO of Archangels from 2005 to 2015 where he grew value in their portfolio and led nine exits. John continues to advise Archangels, sits on the boards of four early-stage companies, Northern 3 Venture Capital Trustand is also involved in advising an Amadeus fund.

    The Board has been impressed with John’s depth of experience and track record of delivering success with multiple early-stage companies, and are confident that as Chairman, John will drive further growth at Biogelx.

    John added, “Biogelx have developed a really unique and differentiated technology and I am looking to working with the team, to establish Biogelx as the ‘go-to’ supplier of synthetic bioinks. The company has a clear business strategy to deliver strong growth, and the Board and I are fully committed to supporting this.”

    For further information, please contact Eszter Vuity, Marketing Manager.

  2. Want to contribute to the development of non-animal technologies to improve drug discovery?

    Leave a Comment

    Looking for a PhD involving cutting edge research that also provides skills highly sought after by employers?

    The lifETIME (Engineered Tissues for Discovery, Industry, and Medicine) CDT is a partnership between the University of Glasgow, University of Birmingham, Aston University, National University of Ireland Galway and industrial partners such as AstraZeneca, Charles River, BioLamina, Biogelx, BASF, InSphero, NHS, etc. The lifETIME CDT will train the next generation of interdisciplinary (engineering, chemistry, physics, maths, and biology) leaders in developing in vitro tissues, sensing, and diagnostics to develop humanised in vitro systems to drive better drug screening. For more information, visit the website:

    The lifETIME CDT programme is a great opportunity for students who are seeking a fully funded PhD research programme to contribute to the development of non-animal technologies to improve pre-clinical drug screens and drive drug discovery. Sound like the opportunity for you? Degree in chemistry, physics, maths, engineering, or life sciences? Apply here (deadline 8th March)


    You might like:

    Why is the application of 3D Bioprinting important in Drug Development?

    Combining High-throughput screening and 3D bioprinting

    Using Bioprinting to Create Better 3D Tumor Models